I. INTRODUCTION
One of the most contentious issues before the World Trade Organization ("WTO") is the application of the Agreement on TradeRelated Aspects of Intellectual Property Rights ("the TRIPS Agreement", "TRIPS", or "the Agreement") to WTO members seeking to facilitate access to essential medicines. Members seek to use these medicines to combat ongoing epidemics such as HIV/AIDS or sudden threats such as the recent anthrax scares following the terrorist attacks on the United States on September 11, 2001 .
Developing countries have argued that the TRIPS Agreement does not limit their sovereignty to address crises such as HIV/AIDS. They view compulsory and parallel licensing as permissible objectives that do not violate the TRIPS Agreement. Developed countries, particularly the United States and Switzerland, have argued that the only flexibility in the TRIPS Agreement is the staggered implementation periods developing countries enjoy under the Agreement. Under the staggered implementation schedule, developing countries have five years and least developed countries have ten years from January 1, 1996, to fully implement the Agreement.
The November 2001 Doha Declaration on TRIPS and Public Health ("the Doha Declaration") was in part necessitated by these divergent perspectives. The WTO's dispute settlement bodies have not directly addressed these divergent interpretations. 1 In addition, the legal effect of a unilateral interpretation of a treaty made by one of the contracting states is not binding upon other contracting states. 2 It is therefore useful to examine the extent to which the Doha Declaration resolves these divergent interpretations.
Under customary international law, treaty interpretation must be based on the text, context, object and purpose, and good faith. Where these methods do not result in a conclusive interpretation, supplementary bases of interpretation may be used. This Article argues that given the divergent interpretations of the TRIPS Agreement, the Doha Declaration should now be regarded as an interpretive element in the 1. WTO panel or appellate body reports "are not binding, except with respect to resolving the particular dispute between the parties to that dispute.' WTO Appellate Body Report, Japan-Taxes on Alcoholic Beverages, WT/DS8/AB/R at 9 (Oct. 4, 1996) . However, such reports could provide guidance to the WTO. See WVTO Appellate Body Report, United States-Tax Treatment For "Foreign Sales Corporations," WT/DSI08/AB/R 115 at 31 (Feb. 24,2000) .
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interpretation of the TRIPS agreement under customary international law.
Part II outlines the rights of patent holders under the TRIPS Agreement and the challenges posed by the ongoing HIV/AIDS pandemic. Part III discusses the negotiations leading to the Doha Declaration. Part IV examines the extent to which the Doha Declaration can be construed as an element in the interpretation of the TRIPS Agreement.
If. PROTECTION OF PATENTS UNDER THE TRIPS AGREEMENT AND THE HIV/AIDS PANDEMIC
The TRIPS Agreement is a product of protracted negotiations at the Uruguay Round that ended in 1994. Like most General Agreement on Tariffs and Trade ("GATT') rules, the negotiations leading to its adoption were "long, unwieldy and exhausting... with substantive negotiations separated by several years." 3 The difficulty of amending GATT/WTO rules has resulted in an "additional complex of related instruments" whose legal status is uncertain. 4 The Doha Declaration was necessary in part due to the unwieldy legislative process surrounding the TRIPS Agreement. 5 The TRIPS Agreement establishes patentability for product and process inventions in all fields of technology, provided they are new, involve an inventive step, and are capable of industrial application. 6 Patent rights must be available "without discrimination as to the place of invention, the field of technology or whether the products are imported or locally produced." 7 The Agreement also guarantees most favored nation treatment for intellectual property rights, and requires members to "ensure that enforcement procedures.. .are available under their law so as to permit effective action against any act of infringe-
See Kenneth W. Abbot, GATT as a Public Institution: The Uruguay Round and
Beyond, 18 BROOK. J. INT'L L. 31, 83 (1992) .
4. JOHN H. JACKSON, RESTRUCTURING THE GATT SYSTEM 26-30 (1990). 5. As Abbot observes, " [t] his kind of legislative process cannot hope to keep pace with changes in practice and perception in the community at large, or to focus sufficient attention on the increasingly complex issues coming onto the international trade agenda." Abbott, supra note 3, at 83. Under the earlier Paris Convention, each country was only obliged to extend intellectual property protection no worse than its own to its trading partners.
2 By requiring minimum levels of protection, the TRIPS Agreement therefore no longer allows countries to choose their level of intellectual property protection.
During the Uruguay negotiations on the TRIPS Agreement, a major goal of the United States, the European Union, Japan, Switzerland, and the Nordic countries was to establish a high level of intellectual property protection with a guarantee of enforcement 13 Developing countries, particularly Brazil, argued that this position focused too much on the interests of owners of intellectual property rights and not enough on those of users. Brazil argued that the Agreement should reflect the needs of developing countries, such as access to technology.
14 During the Uruguay Round, the United States unilaterally pressured developing countries opposed to its negotiating position, such as Brazil, Thailand, and India, using the authority of the United States Trade Representative ("USTR") under super 301.15 Therefore, the Agreement was negotiated within a coercive bargaining context, despite the fact that developing countries won some concessions in return for signing the TRIPS Agreement 6 The issue of access to essential medicines replays the original debate between developing and developed countries regarding the TRIPS Agreement. Developed countries continue to maintain that high levels of intellectual property protection provide the necessary incentive for investment in research and development, which is the best guarantee of access to essential medicines for all countries. In contrast, developing countries maintain that strict constructions of the TRIPS Agreement fail to recognize the legitimate interests of intellectual property rights users, especially in the context of crises such as HIV/AIDS. 69-80 (1990) .
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Though HIV/AIDS is incurable, drugs have made it treatable. For example, in the United States, retroviral drug treatment has quadrupled the median survival time for Americans diagnosed with HIVIAIDS from one to four years. 11 However, HIV/AIDS remains an intractable problem, particularly in developing countries. In subSaharan Africa, over five million people have contracted the virus, half of them between the ages of fifteen and twenty-four. Close to one million of those infected are children. In the former Soviet Union, there are over one million people infected with HIV/AIDS. In 2001, an estimated 30,000 people in Western Europe and another 45,000 in North America became infected. The economic and social impact of the virus has been staggering, particularly in sub-Saharan Africa. Countries, inter-governmental institutions, and non-governmental groups have designed and implemented programs to deliver a variety of services to address this pandemic.'
Rather than presenting the TRIPS Agreement with new challenges, the HIV/AIDS pandemic re-created tensions between developing and developed countries already apparent at the Uruguay Round. The tensions surrounding the Agreement are not merely between developing and developed countries. Tension also exists regarding the * definition of an intellectual property right. If it is conceived in abstract terms as an exclusive power that provides incentives to invest in research, this definition ignores the social context of these rights. 19 The Doha Declaration on TRIPS and Public Health seeks to resolve this tension. 
A. Events Leading to the Declaration
The TRIPS Council held a special session in June 2001 to discuss the interpretation of the TRIPS Agreement. The goal of this special session was to define the relationship between intellectual property rights and access to essential medicines under the Agreement. The goal of the Africa Group and other developing countries was to clarify the extent to which the TRIPS Agreement allows members to promote and protect public health and "other overarching public policy objectives.
20
The Special TRIPS Council heard over forty statements during the meeting on June 20, 2001. The United States argued that a strong patent regime would produce benefits for all countries, while acknowledging the interests of developing countries in access to essential medicines. The European Community's ("E.C.") delegation welcomed the discussion as laying the ground for a fruitful process towards the Doha Ministerial conference. Developing countries continued to emphasize that restrictive interpretations of TRIPS would unduly limit their ability to address public health emergencies such as AIDS.
21
The joint developing country paper endorsed by the Africa Group, the Association of South-East Asian Nations, Brazil, and others presented a common legal interpretation of the TRIPS Agreement.
The immediate challenge facing these countries is the need to lay a legal basis for steps to address the HIV/AIDS pandemic without fear of violating the TRIPS Agreement. This need for legal security is particularly urgent for countries of the Southern Africa region, where HiIV/AIDS infection rates are near thirty percent of their populations. South Africa argued that challenges to its public health legislation by pharmaceutical companies necessitated legal certainty on the scope of the TRIPS Agreement.
By contrast, the United States adopted the position that the TRIPS Agreement strikes a balance between incentives for innovation and access to essential medicines. According to the United States, the developing countries were mistaken to argue that Articles 7 and 8 of the TRIPS Agreement are the backdrop against which the rest of the provisions of the Agreement should be read. Instead, the United States argued that the TRIPS Agreement accommodated developing coun- Legal Status of the Doha Declaration tries by allowing them longer transition periods for compliance. The United States also argued that compulsory licensing under Article 31 should be read together with Article 27.1, which would prevent member countries from taking steps to protect public health and to ensure their citizens' access to essential medicines.
In a follow-up informal meeting of the TRIPS Council on July 25, 2001, the United States and Switzerland declared that they would not endorse any proposal at the WTO Ministerial Conference in Doha that affirmed that the TRIPS Agreement permits countries to take measures to ensure access to essential medicines? 2 Developing countries, led by the Africa Group, proposed six elements to be included in a declaration to be issued at the Doha meeting:
(1) the use of Articles 7 and 8 in the interpretation of all provisions in the TRIPS Agreement; (2) the right of countries to determine the grounds on which compulsory licences may be issued; (3) recognition of compulsory licences issued to a foreign manufacturer; (4) the right to parallel import; (5) a moratorium on all dispute actions aimed at preventing or limiting access to medicines or protection of public health; and (6) extension of transition periods for developing and least developed countries.
23
The United States objected to a separate declaration, arguing that developing and least developed countries had not proven that the TRIPS Agreement limited access to essential medicines.
The United States, E.C., and Switzerland further objected to any discussions at the TRIPS Council of a moratorium on filing dispute settlement actions. They argued that only the General Council had the necessary mandate to discuss this "'political' issue." 24 At a General Council meeting on July 26, 2001, the United States sought to limit any link between TRIPS and public health to AIDS. 25 The United States also argued at the June 2001 TRIPS Council meeting that serious health problems like HIV/AIDS needed a "comprehensive approach," including medical infrastructure, doctors, nurses, and initiatives by multilateral institutions such as the World Health Organization. 26 Developing countries replied that the TRIPS Council did not When the TRIPS Council met on September 19, 2001, it discussed two drafts of a proposed ministerial declaration. The developing country draft 28 asserted that the TRIPS Agreement does not prevent members from taking measures to protect public health. Thus TRIPS does not remove a member's sovereign power to address public health emergencies within its own borders. The developed country draft argued that the most effective strategy for addressing public health emergencies is a combination of economic, social and health policies. 29 These policies require a strong patent regime to encourage the development of new drugs.
Notwithstanding these divergent positions, a Declaration on TRIPS and Public Health was issued by a consensus of all WTO members at the Doha Ministerial meeting in Qatar in November 2001. The Declaration provides in part:
We agree that the TRIPS Agreement does not and should not prevent members from taking measures to protect public health. Accordingly, while reiterating our commitment to the TRIPS Agreement, we affirm that the Agreement can and should be interpreted and implemented in a manner supportive of WTO Members' right to protect public health and, in particular, to promote access to medicines for all.
30
The Declaration acknowledges that HIV/AIDS, tuberculosis, malaria, and other epidemics are grave public health problems afflicting developing countries. It also reaffirms "the right of the WTO Members to use, to the full, the provisions in the TRIPS Agreement, which provide flexibility for this purpose." [Vol. is
IV. THE LEGAL STATUS OF THE DOHA DECLARATION
The Doha Declaration was necessary because interpretation of TRIPS based on the text, context, object and purpose, and good faith did not settle divergent interpretations. My analysis of the legal status of the Doha Declaration under international law discloses at least three possibilities:
(1)
As a subsequent agreement under Article 31 § 3(a) of the Vienna Convention on the Law of Treaties regarding the interpretation of the TRIPS agreement.
(2)
As evidence of subsequent practice establishing the understanding of WTO members regarding interpretation of the TRIPS Agreement. 33 (3)
As a declaration of commitment and intent that does not constitute an enforceable legal obligation.
A treaty should be interpreted in good faith using the ordinary meaning of its terms in context and in light of the treaty's object and purpose. 34 Text, context, object and purpose, and good faith are used "'as one holistic rule of interpretation rather than a sequence of separate tests to be applied in a hierarchical order." 35 Article 31 § 3(a) of the Vienna Convention on the Law of Treaties states that "any subsequent agreement between the parties regarding the interpretation of the treaty or the application of its provisions" shall be considered together with its context in the interpretation of a 38 treaty. The International Law Commission has stated: "an agreement as to the interpretation of a provision reached after the conclusion of the treaty represents an authentic interpretation by the parties which must be read into the treaty for purposes of its interpretation.
39
Article 31 § 3(a) is useful to establish the intent of the parties to a treaty where the text, context, object and purpose, and good faith are incapable of resolving ambiguities.
40 Subsequent agreements reflect the intent of the parties and can be used to interpret the actual terms of the treaty."' Under recent WTO Appellate Body jurisprudence, there is precedent for giving a subsequent agreement between parties to a WTO treaty the same legal status as the WTO treaty. 42 As described in Part III, the Doha Declaration was negotiated over several months by all members of the WTO initially through the TRIPS Council, which in turn made recommendations to the General Council. The General Council then reported to the Ministerial Conference at Doha, which issued the Doha Declaration. The Ministerial Conference has "the authority to take on decisions on all matters under any of the Multilateral Trade Agreements." 43 The Doha Declaration emerged from the WTO decision-making framework and was issued by the Ministerial Conference at Doha. This is consistent with were parties to the Vienna Convention but both of them considered Article 31 applicable "inasmuch as it reflects customary international law." Id. at 18. Similarly and directly relevant, a WTO panel has also held that Article 31 has "attained the status of rules of customary international law. 
The Declaration Proposes a Balancing Approach to Interpretation of the TRIPS Agreement
The Doha Declaration captures the middle ground between the positions adopted by developing and developed countries. It embodies commitment to patent protection for the development of new drugs and to availability of these drugs for indigent populations. The third paragraph in the preamble to the Doha Declaration declares that "[w]e recognize that intellectual property protection is important for the development of new medicines. We also recognize the concerns about its effects on prices. '47 The fourth paragraph of the Declaration fortifies this middle ground by affirming that the "TRIPS Agreement can and should be interpreted and implemented in a manner supportive of WTO Members' right to protect public health and, in particular, to promote access to medicines for all. ' 4 S This language cast in terms of members' rights to protect public health introduces an interpretation not expressly provided in the TRIPS Agreement. Hence these rights are not expressly derived from the TRIPS Agreement, but are exercis- The second part of the fourth paragraph further provides that in "this connection, we affirm the right of WTO Members to use, to the full, the provisions in the TRIPS .Agreement, which provide flexibility for this purpose." 50 This statement is consistent with Appellate Body jurisprudence construing exceptions to WTO commitments. The balancing test embodied in the Doha Declaration was embraced by the Appellate Body in United States-Shrimp Products." In interpreting the chapeau of GATT's Article XX, the Appellate Body held that "the measures falling within the particular exceptions must be applied reasonably, with due regard to both parties.. .concerned. ' 2 In Hormones, this balancing approach was adopted by the Appellate Body to reverse a Panel decision on the burden of proof with regard to exceptions.
53
The Appellate Body held that "merely characterizing a treaty provision as an 'exception' does not by itself justify a 'stricter' or 'narrower' interpretation of that provision than would be warranted by examination of the ordinary meaning of the actual treaty words, viewed in context and in light of the treaty's object and purpose."
The Doha Declaration borrows its balancing approach from the jurisprudence on exceptions that has emerged from other WTO Agreements.
The chapeau of paragraph 5 of the Doha Declaration embraces this balancing approach because the members recognize a number of flexibilities contained therein "while maintaining [their] commitments in the TRIPS Agreement." These flexibilities include: reading each provision of the TRIPS Agreement in light of the object and purpose as expressed in its objectives and principles; 55 the right to grant compulsory licenses and the freedom to determine the grounds upon which such licenses are granted; 55 
Interpreting Specific Provisions of the TRIPS Agreement
The chapeau of Paragraph 5 presupposes that the four flexibilities exist simultaneously with the rights and responsibilities embodied in the TRIPS Agreement. Previous decisions have read the analogous chapeau to Article XX of GATT to restrict exceptions to GATT. 6°R ecently, however, the Appellate Body has held that the object and purpose of such a chapeau is to prevent abuse of the exceptions rather than'to restrict them.6 Hence, to that extent, Paragraph 5 fortifies the availability of the exceptions listed there to members pursuing public health goals in the context of pandemics like AIDS. Furthermore, the Appellate Body's dicta in United States-Shrimp Products supports reading the TRIPS Agreement "in light of contemporary concerns of the community of nations" when dealing with AIDS and similar health pandemics such as tuberculosis and malaria. 62 
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Interpreting the TRIPS Agreement in Light of Its Objectives and Principles
The Doha Declaration supports reading all the provisions of the TRIPS Agreement in light of Articles 7 and 8.63 This reading is further supported by the Appellate Body's reference to Articles 7 and 8 in Canada -Term of Patent Protection, even though neither party specifically referred to these articles in establishing the panel and its jurisdiction. The Appellate Body noted that its ruling did not in any way prejudge "the applicability of Article 7 or Article 8 of the TRIPS Agreement in possible future cases with respect to measures to promote the policy objectives of the WTO members that are set out in those Articles. Those Articles still await appropriate interpretation....,m This reading presupposes that the TRIPS Agreement balances patent protection with access to pharmaceutical products in the context of WTO members facing public health emergencies. Access to pharmaceutical products, however, is only one possible basis for such an interpretation. Other bases could arguably include technology transfers, preventing restraints of trade by patent owners, and linking 63. Articles 7 and 8 are, respectively, the objectives and principles clauses of the TRIPS Agreement. Article 7 notes that: protection and enforcement of intellectual property rights should contribute to the promotion of technological innovation and transfer and dissemination of technology to the mutual advantage of producers and users of technological knowledge and in a manner conducive to social and economic welfare, and to a balance of rights and responsibilities. TRIPS Agreement, supra note 6, at art. 7. Article 8(1) provides that:
Members may, in formulating their laws and regulations, adopt measures necessary to protect public health and nutrition, and to promote the public interest in sectors of vital importance to their socio-economic and technological development, provided that such measures are consistent with the provisions of this agreement. TRIPS Agreement, supra note 6, at art. 8. Article 8(2) provides that:
Appropriate measures, provided that they are consistent with the provisions of this Agreement, may be needed to prevent the abuse of intellectual property rights by right holders or the resort to practices which unreasonably restrain trade or adversely affect the international transfer of technology.
Id.
64 Interpreting the TRIPS Agreement in light of its principles and objectives does not dictate any particular legal outcome. For example, Articles 7 and 8 do not determine the balance between protection of patent rights under Article 27.1 and the right to compulsory licensing in pursuit of a public health program:
[W]hen one is dealing with the object and purpose of a treaty, which is the most important part of the treaty's context, the object and purpose does not constitute an element independent of that context. The object and purpose is not to be considered in isolation from the terms of the treaty; it is intrinsic to its text. It follows that, under Article 31 of the Vienna Convention, a treaty's object and purpose is to be used only to clarify the text, not to provide independent sources of meaning that contradict the clear text.
66
What the Doha Declaration, however, does as a matter of law is not insignificant. 67 It mandates reading the TRIPS Agreement in light of its objectives and principles, thereby giving countries a legal basis in the Agreement itself to argue in favor of public policies. For example, in the Arbitration Proceedings pursuant to Canada -Patent Protection of Pharmaceutical Products (Generic Medicines), 8 Canada argued that that it should have more time to comply with the repeal of the stockpiling provisions in its Patent Act because of the political sensitivity of reversing its "long standing policy of providing relatively low cost medication to consumers as soon as possible." The Panel decision had required Canada to repeal statutory provisions that 
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Harvard Journal of Law & Technology allowed generic drug manufacturers to stockpile patent products prior to the expiration of their patent term in readiness for marketing upon the expiration of the patents. If the Panel had read this provision in light of the TRIPS Agreement's objectives and principles, it might have found in favor of Canada. Indeed, as Robert Howse has observed, the panel implausibly found the stockpiling provisions inconsistent with the TRIPS agreement while upholding the rights of competing generic manufacturers to test patented products prior to the expiration of the period of protection." The Doha Declaration's exhortation that each provision of the TRIPS agreement be read in light of the object and purpose as expressed in its objectives and principles is therefore not inutile for countries in Canada's position. Similarly, the United States 7 was pursuing public health security goals when it considered, but did not invoke, domestic legislation to override Cipro patents during the anthrax scare. 72 The consideration of these goals by a developed country in the context of anthrax lends legitimacy to other countries' consideration of similar goals in the context of public health emergencies such as AIDS.
7 3 In this context, therefore, the Declaration would preclude interpreting the obligations of the TRIPS Agreement solely from the perspective of how the government's policies curtail right holders' interests and would permit consideration of 70. See id. at 498. 71. In the United States, compulsory licensing is not subject to exceptions as those that encumber it in Article 31 of TRIPS. The U.S. government does not have to seek a license or negotiate for use of a patent or copyright. Any federal employee can use or authorize the use of a patent or a copyright under 28 U.S.C § 1498(a). The right owner is entitled to compensation, but cannot enjoin the government or a third party authorized by the government to prevent use. Use by any contractor, subcontractor, person, firm, or corporation who receives authorization from the federal government to use patents or copyrights is construed as use by the federal government, and cannot be sued for infringement. Compensation is not based on lost profits or royalties, but rather on reasonable royalty or, as one court has put it, since compensation is based on eminent domain, the proper measure is "what the owner has lost, not what the taker has gained. ' Leesona Corp. v United States, 599 F.2d. 958, 969 (Ct. Cl. 1979 ). This section explicitly provides that it shall not have extra-territorial effect. 
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Legal Status of the Doha Declaration how the policy safeguards consumers' interests in the provision of low-cost essentials medicine during public health emergencies.
National Emergencies
The TRIPS Agreement does not define what constitutes a national emergency or other circumstance of extreme urgency. The Doha Declaration does specify that HIV/AIDS, tuberculosis, malaria, and other epidemics are all instances of public health crises that can represent national emergencies or other circumstances of extreme urgency. This is a significant elaboration of Article 31, particularly in view of the fact that at the pre-Doha negotiations, the United States had reluctantly indicated that only HIV/AIDS should qualify under the emergency criteria.
74 At the very least, for purposes of public health emergencies, the United States' pre-Declaration position (to the effect that Article 31(b) rights are subject to Article 27.1 patent rights and adequate remuneration) can now safely be said to have been overcome. Pursuant to the Declaration's exhortation that all provisions of the TRIPS Agreement be read in light of its objectives and principles, it is untenable to suggest that the invocation of compulsory licensing under Article 31 to address a public health emergency would necessarily be overridden by the provisions of Article 27.1 on patent rights or even the rights to normal exploitation and legitimate interests of patent owners referred to in Article 30.
According to the Kenya National AIDS HIV/AIDS Strategic Plan 2000-2005:
HIV/AIDS is a great threat to our nation. It has caused deaths of over a million Kenyans since 1984.
There is yet no known cure, and we estimate that over two million out of our total population of 29 million are living with HIV/AIDS. The rate of infection is rising and it is unlikely that an effective affordable cure or vaccine will be developed in the near future. It is for these reasons that my Government declared HIV/AIDS a national disaster on 25 November 1999.75 The report details the impact of HIVY/AIDS on education, agriculture, health, social services, the industrial sector, and the armed forces. 
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The Kenya Industrial Property Act of 2001 waives the preconditions for providing compulsory licenses "in the case of a national emergency or other circumstances of extreme urgency, provided the owner of the patent shall be so notified as soon as is reasonably practicable. ' 76 Issuing these compulsory licenses, then, would not violate the TRIPS Agreement in light of the national AIDS emergency.
The Freedom to Establish Their Regimes of Exhaustion Without
Challenge but Subject to the MFN and National Treatment Provisions Paragraph 5(d) of the Declaration provides that "the effect of the provisions in the TRIPS Agreement that are relevant to the exhaustion of intellectual property rights is to leave each member free to establish its own regime for such exhaustion without challenge, subject to the MFN and national treatment of Articles 3 and 4."
To what extent does the Doha Declaration clarify Article 6 of the TRIPS Agreement regarding exhaustion of rights? 7 Article 6 provides that none of its provisions, except those dealing with nondiscrimination, national treatment, and most favored nation, can be used to address the issue of exhaustion of intellectual property rights in a WTO dispute. Exhaustion means that once a patent holder has sold a patented invention, the patent holder has no further right to exclude others from subsequent use, including offering to sell or distribute the patented invention. In essence, exhaustion presupposes that the patent owner, unless there is an agreement to the contrary, implicitly licenses the subsequent use and resale of a patented product upon first sale.
Since January 1, 1996, U.S. patent owners have had the right to exclude others from offering to sell a patented invention in the United States and from importing the invention into the United States. 78 Hence under U.S. law, if a firm in a second country makes and sells a U.S. patent owner's product and imports it into the United States, the importation would constitute a violation of U.S. law.
79 If the product § 271(a) (1994) . For an early case, see Dunlop Co., Ltd. v. Kelsey-Hayes Co., 484 F.2d 407 (6th Cir. 1973 Legal Status of the Doha Declaration was under patent protection in the second country, that firm would be in violation of the TRIPS Agreement. In the European Union ("EU"), the sale of a patent license by the consent of the patent holder exhausts the patent holder's right to the good and the patent holder cannot oppose the use of it by others in subsequent transactions. However, the EU, like the United States, does not recognize international exhaustion. Hence, if the sale is made outside of the EU and is subsequently distributed in the EU, the patent holders rights to control the price or permit the licensee to sell it still exist. 80 Both the EU and the United States therefore have protectionist regimes that forestall competition from cheaper foreign manufacturers. In contrast, developing countries maintain that they have a right to determine whether or not to allow parallel imports. Unlike the United States and the EU, they argue that patent holders should not have the right to allow parallel imports. The Declaration is supportive of every member of the WTO establishing their own regime of exhaustion as long as it complies with the non-discriminatory obligations of the TRIPS Agreement. This is a significant legal clarification in view of pre-Doha controversies regarding the scope of a WTO member's right to define its own regime of exhaustion. This clarifica--tion might result in a bifurcated regime of exhaustion among WTO members. Countries seeking to promote public health programs such as affordable medicines or access to essential drugs during a health crisis might adopt an international exhaustion regime under which right holders cannot take action against parallel imports. The right established by the Declaration for countries to determine what constitutes a national emergency increases and strengthens sovereignty to establish international exhaustion regimes. Once a country determines that it faces a health emergency, it can then seek to import drugs from another country where the right holder has licensed the drug. By contrast, countries with big pharmaceutical industries such as the United States might seek to maintain their present regimes of exhaustion under which right holders can take action against parallel importers.
Extension of Compliance Periods for Least Developed Countries
Paragraph 7 of the Declaration provides a major concession to least developed countries. Prior to Doha, the Agreement required ent is not the same person who has made or authorized the sale abroad. 
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Harvard Journal ofLaw & Technology compliance from January 1, 2006.81 Now the least developed countries have until 2016 to come into compliance with the TRIPS Agreement. This ten year extension, without prejudice to these countries to seek further extensions, only applies to pharmaceutical products, and as such only delays implementation of Sections 5 and 7 of Part II of the TRIPS Agreement.
B. The Doha Declaration as Evidence of Subsequent Practice Under the TRIPS Agreement
Article 31 § 3(b) of the Vienna Convention on the Law of Treaties describes the role of subsequent practice in treaty interpretation: "subsequent practice . . . establishes the agreement of the parties regarding its interpretation." 8 2 The word "agreement" was included in the final draft of the Vienna Convention on the Law of Treaties as a replacement for the word "understanding" as a way of conforming the English version of the treaty with the Spanish, Russian, and French versions.
8 3 Hence, the word "agreement" in the English text has the same meaning as the French accord or the Spanish acuerdo; "agreement" includes both agreement in writing, such as the Doha Declaration, as well as agreement manifested by conduct, such as subsequent practice.
84
Sir Gerald Fitzmaurice has argued:
[T]he way in which the parties have actually conducted themselves in relation to the treaty affords legitimate evidence as to its correct interpretation.... 'N 51, 99 (1966) . Similarly, the Court of Arbitration in the Beagle Channel Arbitration observed:
[Tihe court cannot accept the contention that no subsequent conduct, including acts ofjurisdiction, can have probative value as a subsidiary method of interpretation unless representing a formally stated or acknowledged "agreement" between the Parties. The terms of the Vienna Convention do not specify the ways in which "agreement" may be manifested. Case Concerning a Dispute Between Argentina and Chile Concerning the Beagle Channel, 21 R.I. A.A. 55, 187 (1977) .
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[C]onduct usually forms a more reliable guide to intention and purpose than anything to be found for instance in the preparatory work of the treaty, simply because it has taken concrete and active, and not merely verbal or paper, form. 5 For example, in a 1963 arbitration decision between the United States and France, subsequent practice of the two parties was held relevant to the interpretation of the governing 1946 treaty. Subsequent practice was interpreted as tacit consent to modify the treaty "not by virtue of the Agreement of 1946 but rather by virtue of an agreement that implicitly came into force at a later date." 8 6 U.S. courts have also relied on subsequent practice to interpret ambiguous treaty provisions. For example, the Second Circuit has relied on subsequent conduct to find that the term "accident" as used in the Warsaw Convention in the context of liability for aviation accidents includes hijackings. 8 7 Therefore consensus or common understanding between WTO members manifested by conduct can provide important guidelines on the interpretation and implementation of the words of the TRIPS Agreement. The Doha Declaration evidences the embryonic stages of subsequent practice, which can therefore establish agreement of WTO members regarding interpretation of specific provisions of the TRIPS Agreement. As elucidated in Part III(a), the Doha Declaration allows nations additional flexibility under TRIPS with regard to interpreting TRIPS in light of its objectives and principles, granting compulsory licenses, defining national emergencies, and establishing regimes of exhaustion. To the extent these options under the Doha Declaration are utilized by WTO members, they help constitute subsequent practice that can be used in interpreting the TRIPS Agreement.
Other decisions and policies adopted by WTO members may constitute subsequent practice under TRIPS. For example, the United States withdrew a trade dispute filed under the WTO's Dispute Set- grant compulsory licenses for failure to work patents it had granted., 3 9 Brazil argued that the law was necessary to encourage patent holders to manufacture their drugs in Brazil at affordable prices and to facilitate technology transfer. The contemporaneous withdrawal of the complaint with the commencement of the United Nations General Assembly special session on HIV/AIDS and the TRIPS Council special session symbolized a movement towards balancing patent protection and health concerns. 90 1999) . Under this section, the United States Trade Representative ("USTR") is required within thirty days after the submission of the annual National Trade Estimates (foreign trade barriers) to report to Congress those foreign countries that (1) deny adequate and effective protection of U.S. intellectual property rights and (2) those countries under (1) that are determined by the USTR to be priority foreign countries. The USTR identifies as priorities only those countries that have the most onerous or egregious acts, policies, or practices that have the greatest adverse impact on the relevant United States products and that are not entering good faith negotiations or making significant progress in bilateral and multilateral negotiations to provide adequate and effective intellectual property rights protection. Id.
The United States has maintained that Doha was a political declaration with no legal authority. The United States Trade Representative's Fact Sheet summarizing the results of the Doha meeting refers to the Doha Declaration on TRIPS and Public Health as a political declaration. 1°6 From this perspective, the Declaration is not a fait accompli for countries seeking to facilitate access to essential medicines. Rather, it is an implicit reciprocation by the West to developing country governments for their implementation of the TRIPS Agreement and their acquiescence to a new round of WTO talks.
1 0 7 The United States in particular would have been unwilling to sign the Declaration had it suspended the legal obligations of developing countries under TRIPS.
Distinguishing legal claims from non-legal or political claims, such as access to essential medicines, can deprive them of their status as rights and thereby serve to legitimize an unjust status quo. As Richard Bilder argued more than three decades ago, " [t] o assert that a particular social claim is a human right is to vest it emotionally and morally with an especially high order of legitimacy." 10 8 Asserting that a particular claim is not a right not only denies disempowered peoples the potentially transformative value of rights, 1 0 9 but also robs their claims of legitimacy in the moral currency of international relations. 110 This denial results from the conceptualization of certain claims as political, social, or public, so that as a result they fall outside and cannot disturb the private commercial or contractual character of trade, financial, or banking regimes.' For example, the Second Cir-
